최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기생명과학회지 = Journal of life science, v.29 no.11, 2019년, pp.1267 - 1272
강창수 (부산의료원 병리과) , 이경은 (부산가톨릭대학교 임상병리학과)
The main cause of cervical cancer is the human papillomavirus (HPV), and HPV DNA has been reported in 99.7% of patients with cervical cancer. The worldwide prevalence is highest for the HPV 16 and 18 genotypes, but HPV 52 and 58 have the highest prevalence in Asian countries, including Korea. The pu...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
자궁경부암의 주요 원인은 무엇인가? | 자궁경부암의 주요 원인은 인유두종 바이러스(HPV)로 알려져 있으며, 자궁경부암 환자의 99.7%에서 HPV DNA가 검출된다고 하였다. | |
HPV는 몇 종의 유전자형이 있는가? | HPV는 이중 나선상 DNA 바이러스로 180여종의 유전자형이 있으며, 이 중에서 30~40종의 유전자형이 여성생식기에 감 염을 일으킨다고 알려져 있다[23]. 저위험군 인유두종 바이러 스(Low Risk-HPV, LR-HPV)는 HPV 6형과 11형을 포함하여 여성생식기의 양성변화를 일으키고, 고위험군 인유두종 바이 러스(High Risk-HPV, HR-HPV)는 HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66형 등으로 자궁경부암 발생과 관련이 있는 것으로 알려져 있다[1]. | |
HPV DNA 진단 및 연구의 목적은 무엇인가? | 최근 국내에서는 HPV가 자궁경부암의 주요 원인으로 알려 지면서 HPV DNA 진단 및 연구가 활발히 진행되고 있는 실정이다. 기존에 시행되던 자궁경부 세포 검사와 병행하여 시행 하고 있으며, 이는 HPV 감염에 대한 선별 검사 및 HPV 유전자형 분석을 통해 고위험군에 대한 잠재적 위험을 확인하고 추적 관찰하고자 하는 목적을 가지고 있다[13, 14]. |
Bernard, H. U., Chan, S. Y., Manos, M. M., Ong, C. K., Villa, L. L., Delius, H., Peyton, C. L., Bauer, H. M. and Wheeler, C. M. 1994. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence and phylogenetic algorithms. J. Infect. Dis. 170, 1077-1085.
Bosch, F. X., Burchell, A. N., Schiffman, M., Giuliano, A. R., de Sanjose, S., Bruni, L., Tortolero-Luna, G., Kjaer, S. K. and Munoz, N. 2008. Epidemiology and natural history of human papillomavirus infections and type-specific implications in Cervical Neoplasia. Vaccine 10, 1-16.
Castle, P. E. 2004. Beyond human papillomavirus: the cervix, exogenous secondary factors, and the development of cervical precancer and cancer. J. Low. Genit Tract. Dis. 8, 224-230.
Chan, K. S., Li, W. H., Chan, Y. M., Ma, W. L., Cheung, J. L. and Cheng, A. F. 1999. High prevalence of human papillomavirus type 58 in china women with cervical cancer and precancerous lesion. J. Med. Virol. 59, 232-238.
Clifford, G. M., Gallus, S., Herrero, R., Munoz, N., Snijders, P. J., Vaccarella, S., Anh, P. T., Ferreccio, C., Hieu, N. T., Matos, E., Molano, M., Rajkumar, R., Ronco, G., de Sanjose, S., Shin, H. R., Sukvirach, S., Thomas, J. O., Tunsakul, S., Meijer, C. J. and Franceschi, S. 2005. IARC HPV Prevalence Surveys Study Group. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366, 991-998.
Cubie, H.A. 2013. Diseases associated with human papillomavirus infection. Virology 445, 21-34.
De Sanjose, S., Diaz, M., Castellsague, X., Clifford, G., Bruni, L., Munoz, N. and Bosch, F. X. 2007. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect. Dis. 7, 453-459.
Herrero, R., Hildesheim, A., Bratti, C., Sherman, M. E., Hutchinson, M., Morales, J., Balmaceda, I., Greenberg, M. D., Alfaro, M., Burk, R. D., Wacholder, S., Plummer, M. and Schiffman, M. 2000. Population-based study of human papillomavirus infection and cervical neoplasia in Rural Costa Rica. J. Natl. Cancer inst. 92, 464-473.
Ho, G. Y., Bierman, R., Beardsley, L., Chang, C. J. and Burk, R. D. 1998. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338, 423-428.
Hwang, H. S., Park, M., Lee, S. Y., Kwon, K. H. and Pang, M. G. 2004. Distribution and prevalence of human papillomavirus genotypes in routine pap smear of 2,470 Korean women determined by DNA chip. Cancer Epidemiol. Biomarkers Prev. 13, 2153-2156.
Jung, K. W., Won, Y. J., Kong, H. J., Lee, E. S. and The Community of Population-Based Regional Cancer Registries. 2018. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015. Cancer Res. Treat. 50, 303-316.
Koutsky, L. A., Holmes, K. K., Critchlow, C. W., Stevens, C. E., Paavonen, J., Beckmann, A. M., DeRouen, T. A., Galloway, D. A., Vernon, D. and Kiviat, N. B. 1992. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N. Engl. J. Med. 327, 1272-1278.
Lee, D. S., Kim, S. H., Park, S. J., Kim, T. U., Jin, H. W., Park, K. H. and Lee, H. Y. 2011. Human papillomavirus prevalence in gangwon province using reverse blot hybridization assay. Kor. J. Pathol. 45, 348-353.
Lee, J. K. 2006. HPV DNA test as a Diagnostic tool for cervical cancer. Obstet. Gynecol. Sci. 49, 261-275.
Myers, E. R., McCrory, D. C., Nanda, K., Bastian, L. and Matchar, D. B. 2000. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am. J. Epidemiol. 151, 1158-1171.
Malagon, T., Drolet, M., Boily, M. C., Franco, E. L., Jit, M., Brisson, J. and Brisson, M. 2012. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 12, 781-789.
Min, K. J., Kwon, S. H., Kim, S. H., Kim, H. J., Seong, S. J., Song, Y. J., Shin, J. W., Lee, K. H., Lim, M. C., Chung, H. H., Ju, W., Hong, J. H., Kim, J. W., Bae, D. S. and Lee, J. K. 2016. Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline. J. Gynecol. Oncol. 27, 1-14.
Nah, E. H., Cho, S., Kim, S. Y. and Cho, H. I. 2017. Human papillomavirus genotype fistribution among 18,815 Women in 13 Korean cities and relationship with cervical cytology findings. Ann. Lab. Med. 37, 426-433.
Ostor, A. G. 1993. Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol. Pathol. 12, 186-192.
Ouh, Y. T., Min, K. J., Cho, H. W., Ki, M., Oh, J. K., Shin, S. Y., Hong, J. H. and Lee, J. K. 2018. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014-2016. J. Gynecol. Oncol. 29, 1-10.
Pinto, A. P. and Crum, C. P. 2000. Natural history of cervical neoplasia: defining progression and its consequence. Clin. Obstet. Gynecol. 43, 352-362.
Richart, R. M. and Barron, B. A. 1969. A follow-up study of patients with cervical dysplasia. Am. J. Obstet. Gynecol. 105, 386-393.
Soto-De, L. S., Camargo, M., Sanchez, R., Munoz, M., Perez-Prados, A., Purroy, A., Patarroyo, M. E. and Patarroyo, M. A. 2011. Disribution patterns of infection with multiple types of human papillomaviruses and their association with risk factors. PLoS One 6, e14705.
Sasagawa, T., Basha, W., Yamazaki, H. and Inoue, M. 2001. High risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women. Cancer Epidemiol. Biomarkers Prev. 10, 45-52.
Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X., Kummer, J. A., Shah, K. V., Snijders, P. J., Peto, J., Meijer, C. J. and Munoz, N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12-19.
WHO. 2014. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly. Epidemiol. Rec. 89, 465-491.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.